Effective exosomes reduction in hypercholesterinemic patients suffering from cardiovascular diseases by lipoprotein apheresis: Exosomes apheresis

被引:0
|
作者
Schroeder, Sophie [1 ]
Epple, Robert [1 ]
Fischer, Andre [1 ,2 ,3 ]
Schettler, Volker J. J. [4 ,5 ]
机构
[1] German Ctr Neurodegenerat Dis DZNE Gottingen, Dept Epigenet & Syst Med Neurodegenerat Dis, Gottingen, Germany
[2] Univ Med Ctr Gottingen, Dept Psychiat & Psychotherapy, Gottingen, Germany
[3] Univ Gottingen, Cluster Excellence Multiscale Bioimaging Mol Machi, Gottingen, Germany
[4] Ctr Nephrol Gottingen GbR, Gottingen, Germany
[5] Nephrol Zentrum Gottingen GbR, An der Lutter 24, D-37075 Gottingen, Germany
关键词
coronary heart disease; exosomes; hemodialysis; lipoprotein apheresis; risk reduction; EXTRACELLULAR VESICLES; ATHEROSCLEROSIS; MICROPARTICLES; RISK;
D O I
10.1111/1744-9987.14172
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IntroductionExtracellular vesicles (EVs) have been identified as playing a role in atherosclerosis.MethodsA group of 37 hypercholesterolemic patients with atherosclerotic cardiovascular diseases (ASCVD) and 9 patients requiring hemodialysis (HD) were selected for the study.ResultsEVs were comparably reduced by various LA methods (Thermo: 87.66% +/- 3.64, DALI: 87.96% +/- 4.81, H.E.L.P.: 83.38% +/- 11.98; represented as SEM). However, LDL-C (66%; 55%; 75%) and Lp(a) (72%; 67%; 79%) were less effectively reduced by DALI. There was no significant difference in the reduction of EVs when comparing different techniques, such as hemoperfusion (DALI; n = 13), a precipitation (H.E.L.P.; n = 5), and a double filtration procedure (Thermofiltration; n = 19). Additionally, no effect of hemodialysis on EVs reduction was found.ConclusionsThe study suggests that EVs can be effectively removed by various LA procedures, and this effect appears to be independent of the specific LA procedure used, as compared to hemodialysis.
引用
收藏
页码:863 / 870
页数:8
相关论文
共 50 条
  • [21] LONG-TERM LIPID APHERESIS REDUCES CARDIOVASCULAR EVENTS IN HIGH-RISK PATIENTS WITH ISOLATED LIPOPROTEIN(A) ELEVATION
    Hollstein, T.
    Schumann, F.
    Kassner, U.
    Spira, D.
    Bobbert, T.
    Steinhagen-Thiessen, E.
    ATHEROSCLEROSIS, 2023, 379
  • [22] Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease Prospective Observational Multicenter Study
    Leebmann, Josef
    Roeseler, Eberhard
    Julius, Ulrich
    Heigl, Franz
    Spitthoever, Ralf
    Heutling, Dennis
    Breitenberger, Paul
    Maerz, Winfried
    Lehmacher, Walter
    Heibges, Andreas
    Klingel, Reinhard
    CIRCULATION, 2013, 128 (24) : 2567 - 2576
  • [23] Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines
    Klingel R.
    Heibges A.
    Fassbender C.
    Clinical Research in Cardiology Supplements, 2017, 12 (Suppl 1) : 38 - 43
  • [24] Mesenchymal stem cell-derived exosomes in cardiovascular and cerebrovascular diseases: From mechanisms to therapy
    Pan, Yanhong
    Wu, Weipeng
    Jiang, Xiaoxin
    Liu, Yunhong
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 163
  • [25] Selective C-reactive protein apheresis for Covid-19 patients suffering from organ damage
    Kayser, Stefan
    Kunze, Rudolf
    Sheriff, Ahmed
    THERAPEUTIC APHERESIS AND DIALYSIS, 2021, 25 (02) : 251 - 252
  • [26] EXCRETION OF UROBILINOGEN IN THE URINE IN PATIENTS SUFFERING FROM CARDIOVASCULAR DISEASES
    FOCHT, FS
    HANSON, HT
    AMERICAN JOURNAL OF MEDICINE, 1948, 4 (05): : 787 - 787
  • [27] Treatment with HELP-Apheresis in Patients Suffering from Sudden Sensorineural Hearing Loss: A Prospective, Randomized, Controlled Study
    Bianchin, Giovanni
    Russi, Gianpaolo
    Romano, Nicola
    Fioravanti, Paola
    LARYNGOSCOPE, 2010, 120 (04): : 800 - 807
  • [28] The incidence of cardiovascular events is largely reduced in patients with maximally tolerated drug therapy and lipoprotein apheresis. A single-center experience
    Sampietro, T.
    Sbrana, F.
    Bigazzi, F.
    Ripoli, A.
    Dal Pino, B.
    Pasanisi, E. M.
    Petersen, C.
    Coceani, M.
    Luciani, R.
    Pianelli, M.
    ATHEROSCLEROSIS SUPPLEMENTS, 2015, 18 : 268 - 272
  • [29] Impact of lipoprotein apheresis with dextran-sulfate adsorption on the expression of genes involved in cardiovascular health in the blood of patients with homozygous familial hypercholesterolemia
    Drouin-Chartier, Jean-Philippe
    Tremblay, Andre J.
    Bergeron, Jean
    Laflamme, Nathalie
    Lamarche, Benoit
    Couture, Patrick
    JOURNAL OF CLINICAL APHERESIS, 2018, 33 (01) : 104 - 107
  • [30] Impact of lipoprotein apheresis on thrombotic parameters in patients with refractory angina and raised lipoprotein(a): Findings from a randomized controlled cross-over trial
    Khan, Tina Z.
    Gorog, Diana A.
    Arachchillage, Deepa J.
    Ahnstrom, Josefin
    Rhodes, Samantha
    Donovan, Jacqueline
    Banya, Winston
    Pottle, Alison
    Barbir, Mahmoud
    Pennell, Dudley J.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2019, 13 (05) : 788 - 796